Skip to main content
Premium Trial:

Request an Annual Quote

Bio-Quant Creates GPCR-Screening Division

NEW YORK, Sept. 5 - Bio-Quant has created a new division designed to offer screening technology for G protein-coupled receptors, the company said on Wednesday.

GPCRs function as the delivery mechanism for more than 50 percent of all drugs currently on the market. To facilitate the discovery of additional GPCRs that might serve as drug targets, Bio-Quant’s new business unit will provide platforms that screen for cell motility and GPCR activation.

“These two platforms for drug discovery will allow biotechnology/pharmaceutical companies to screen their compound libraries much faster and cheaper, enabling them to get to market much sooner,” Bio-Quant CEO Bassam Damaj said in a statement.

As part of the cell motility, or chemotaxis, platform, San Diego-based Bio-Quant’s new division will offer leakage-resistant fluorescent dyes, chemotaxis assays, and imaging devices with liquid-handling capabilities. 

The cell activation platform, also called the intracellular calcium mobilization measurement platform, includes fluorescent CalciDyes and a microplate imaging device.

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.